TrialNature communications2026

Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

Vicente Valero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.